Skip to main content
S&P 5007,636.31+1.12%DOW51,808.37+0.67%NASDAQ26,393.18+1.60%BTC$76,547.00+0.91%ETH$2,453.08+2.03%GOLD$4,390.70+0.07%OIL$101.91-0.51%
Smart Investors Daily
DA

NASDAQ · DARE

Daré Bioscience, Inc.

Healthcare · Biotechnology

$0.73

Up+$0.03 (+4.16%)

Updated Sep 17, 2026, 6:18 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
19.81M
P/E ratio
-1.52
Dividend yield
0.00%
52-week range
$0.69 – $3.78
Volume
135.5K
Avg. volume
140.35K

Price performance

DARE price history

1M range · 20 trading sessions · Daily adjusted prices

DARE closed at $0.73 after 20 trading sessions, down 12.00% for the selected period.

Last close
$0.73
Period change
-12.00%
Period low
$0.71
Period high
$0.82
Daily close
View OHLC price history
DARE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$0.732$0.7593$0.724$0.7255135.5K
Sep 15, 2026$0.7413$0.7713$0.72$0.7301109.23K
Sep 14, 2026$0.7064$0.75$0.691$0.7363426.37K
Sep 11, 2026$0.717$0.7233$0.705$0.70693.72K
Sep 10, 2026$0.70$0.7247$0.70$0.7051103.44K
Sep 9, 2026$0.729$0.7299$0.691$0.7166175.32K
Sep 8, 2026$0.7299$0.737$0.701$0.713191.71K
Sep 4, 2026$0.70$0.7573$0.70$0.721437.48K
Sep 3, 2026$0.7512$0.779$0.69$0.7131450.3K
Sep 2, 2026$0.78$0.797$0.74$0.74249.08K
Sep 1, 2026$0.744$0.797$0.7301$0.7702462.69K
Aug 31, 2026$0.76$0.82$0.7302$0.761640.46K
Aug 28, 2026$0.758$0.758$0.72$0.735356.18K
Aug 27, 2026$0.751$0.7799$0.7301$0.7387428.62K
Aug 26, 2026$0.8332$0.8472$0.74$0.7506954.74K
Aug 25, 2026$0.818$0.8544$0.80$0.8207618.67K
Aug 24, 2026$0.82$0.8448$0.80$0.8015434.9K
Aug 21, 2026$0.80$0.85$0.80$0.8199347.65K
Aug 20, 2026$0.82$0.86$0.78$0.8092502.94K
Aug 19, 2026$0.7675$0.85$0.7622$0.8244711.64K

Latest DARE news

The latest Smart Investors Daily articles mentioning DARE.

Stock researchCompany · Overview

DARE research

Overview

Company profile and research snapshot.

Company profile

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
DARE recent ratings
DateFirmRatingTarget
Dec 2, 2025HC Wainwright & Co.Buy—
Sep 4, 2025Maxim GroupBuy—
Apr 1, 2025HC Wainwright & Co.Buy—
Dec 17, 2024HC Wainwright & Co.Buy—
Nov 15, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 11, 2026

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

View the video webcast here SAN DIEGO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here. The presentation, featuring Sabrina Martucci Johnson, President and Chief Executive

Yahoo · Aug 31, 2026

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million DARE-PTB2 is an early-stage, investigational program focused on developing a potential new therapeutic approach for the prevention of preterm birth SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's heal

Yahoo · Aug 27, 2026

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Video webcast now available here SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated in the Virtual Investor “Why Now” on-demand series. For the webcast, Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, presented the Company's investment thesis, highlig

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By